Medical Oncologists/ Nicholas J. Vogelzang, MD
Dr. Vogelzang received his medical degree from the University of Illinois in Chicago. He completed his internship and residency in Internal Medicine at Rush Presbyterian St. Luke’s Medical Center in Chicago and he completed his fellowship in Medical Oncology at the University of Minnesota in Minneapolis. He was a faculty member at the University of Chicago from 1983 to 2003.
AREAS OF SPECIAL INTEREST
Genitourinary malignancies (prostate, kidney, bladder and testicular cancer) and mesothelioma
Dr. Vogelzang is a renowned medical oncologist and cancer researcher who has authored/coauthored numerous peer-reviewed articles, book chapters and abstracts and has given hundreds of lectures and presentations to his peers. He is currently the associate editor of the peer-reviewed journal, Clinical Genitourinary Cancer. Dr. Vogelzang joined Comprehensive Cancer Centers of Nevada (CCCN) as a medical oncologist in 2009 and he also serves as Chair and Medical Director of the Developmental Therapeutics Committee and Co-Chair of the Genitourinary Committee for US Oncology Research. Prior to joining CCCN, Dr. Vogelzang was Director of the Nevada Cancer Institute from 2004 to 2009. His other prior experience includes serving as the Director of the University of Chicago Cancer Research Center.
MEMBERSHIPS IN PROFESSIONAL ASSOCIATIONS
American Association of Cancer Research
American College of Physicians
American Society of Clinical Oncology
American Urological Association
Chicago Urological Society
Clark County Medical Society
European Society for Medical Oncology
International Association for the Study of Lung Cancer
Kidney Cancer Association
Nevada Oncology Society
Society of Urologic Oncology
Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology., Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, Janne PA, Ko AH, Masters GA, Odenike O, Patel JD, Roth BJ, Samlowski WE, Seidman AD, Tap WD, Temel JS, Von Roenn JH, Kris MG., J Clin Oncol. 2012 Jan 1;30(1):88-109. Epub 2011 Dec 5. PMID: 22147736 [PubMed – indexed for MEDLINE] Read more.
Treatment of patients with metastatic urothelial cancer “unfit” for Cisplatin-based chemotherapy., Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg CN, Bajorin DF, Bellmunt J., J Clin Oncol. 2011 Jun 10;29(17):2432-8. Epub 2011 May 9. Review., PMID: 21555688 [PubMed – indexed for MEDLINE] Read more.
Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study., Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP, Wood DP Jr, Sakr WA, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson IM, Glode LM., J Clin Oncol. 2011 May 20;29(15):2040-5. Epub 2011 Apr 18. PMID: 21502546 [PubMed – indexed for MEDLINE] Read more.
Secondary hormonal manipulations in the treatment of castration refractory prostate cancer., Agarwal N, Vogelzang NJ., BJU Int. 2011 Jul;108(2):227-8. doi: 10.1111/j.1464-410X.2010.09970.x. Epub 2010 Nov 24. No abstract available. PMID: 21410863 [PubMed – indexed for MEDLINE] Read more.
A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy., Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg C, Bajorin DF, Bellmunt J., Lancet Oncol. 2011 Mar;12(3):211-4. No abstract available. PMID: 21376284 [PubMed – indexed for MEDLINE] Read more.
You can find more information about Dr. Vogelzang on Wikipedia.